4.5 Article

IκB Kinase α Phosphorylation of TRAF4 Downregulates Innate Immune Signaling

期刊

MOLECULAR AND CELLULAR BIOLOGY
卷 32, 期 13, 页码 2479-2489

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/MCB.00106-12

关键词

-

资金

  1. NIH [R01GM86550-01, P01DK091222, R01DK082437, R01GM056203]
  2. Burroughs Wellcome Career Award for Biomedical Scientists [10061206.01]

向作者/读者索取更多资源

Despite their homology, I kappa B kinase alpha (IKK alpha) and IKK beta have divergent roles in NF-kappa B signaling. IKK beta strongly activates NF-kappa B while IKK alpha can downregulate NF-kappa B under certain circumstances. Given this, identifying independent substrates for these kinases could help delineate their divergent roles. Peptide substrate array technology followed by bioinformatic screening identified TRAF4 as a substrate for IKK alpha. Like IKK alpha, TRAF4 is atypical within its family because it is the only TRAF family member to negatively regulate innate immune signaling. IKK alpha's phosphorylation of serine-426 on TRAF4 was required for this negative regulation. Binding to the Crohn's disease susceptibility protein, NOD2, is required for TRAF4 phosphorylation and subsequent inhibition of NOD2 signaling. Structurally, serine-426 resides within an exaggerated beta-bulge in TRAF4 that is not present in the other TRAF proteins, and phosphorylation of this site provides a structural basis for the atypical function of TRAF4 and its atypical role in NOD2 signaling.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

Felipe Batalini, Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley, Geoffrey Shapiro, Viktor Adalsteinsson, Eric P. Winer, Panagiotis A. Konstantinopoulos, Alan D'Andrea, Elizabeth M. Swisher, Ursula A. Matulonis, Gerburg M. Wulf, Erica L. Mayer

Summary: This study aimed to evaluate the safety and recommended dose of olaparib in combination with alpelisib in patients with breast cancer, and explore its effects on different subtypes. The results showed that this combination therapy was tolerable for pre-treated TNBC patients and demonstrated activity in non-BRCA mutant patients. Analysis of circulating-free DNA also provided important prognostic information.

CLINICAL CANCER RESEARCH (2022)

Correction Biochemistry & Molecular Biology

Tuberous Sclerosis Complex Gene Products, Tuberin and Hamartin, Control mTOR Signaling by Acting as a GTPase-Activating Protein Complex toward Rheb (vol 13, pg 1259, 2003)

Andrew R. Tee, Brendan D. Manning, Philippe P. Roux, Lewis C. Cantley, John Blenis

CURRENT BIOLOGY (2022)

Review Oncology

Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer

Giulia Petroni, Lewis C. Cantley, Laura Santambrogio, Silvia C. Formenti, Lorenzo Galluzzi

Summary: Targeted anticancer agents have been successful in inhibiting specific molecular alterations in cancer cells, while radiotherapy activates cytotoxic pathways and protective mechanisms that can enhance the efficacy of these agents. By promoting non-oncogene dependence on targetable signaling pathways, radiotherapy has the potential to benefit a greater number of patients who may not respond to targeted therapies alone.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

Correction Oncology

Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer (vol 19, pg 114, 2022)

Giulia Petroni, Lewis C. Cantley, Laura Santambrogio, Silvia C. Formenti, Lorenzo Galluzzi

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

Review Oncology

At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy

Neil Vasan, Lewis C. Cantley

Summary: This review discusses the efforts made in the past and present to improve the clinical efficacy of PI3K pathway inhibitors in cancer treatment, including optimizing inhibitor specificity, patient selection, and biomarkers. It highlights the advantages and limitations of laboratory-based model systems and proposes technologies and experiments to guide the future clinical deployment of PI3K pathway inhibitors.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

Editorial Material Oncology

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission

Kenneth C. Anderson, Lewis C. Cantley, Riccardo Dalla-Favera, Chi Van Dang, Luis A. Diaz, Raymond N. DuBois, Keith T. Flaherty, Philip D. Greenberg, Massimo Loda, Elaine R. Mardis, Elizabeth A. Platz, Michael N. Pollak, Robert D. Schreiber, Lillian L. Siu, Beverly A. Teicher

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2022)

Editorial Material Oncology

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission

Kenneth C. Anderson, Lewis C. Cantley, Riccardo Dalla-Favera, Chi Van Dang, Luis A. Diaz, Raymond N. DuBois, Keith T. Flaherty, Philip D. Greenberg, Massimo Loda, Elaine R. Mardis, Elizabeth A. Platz, Michael N. Pollak, Robert D. Schreiber, Lillian L. Siu, Beverly A. Teicher

CANCER PREVENTION RESEARCH (2022)

Editorial Material Oncology

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission

Kenneth C. Anderson, Lewis C. Cantley, Riccardo Dalla-Favera, Chi Van Dang, Luis A. Diaz, Raymond N. DuBois, Keith T. Flaherty, Philip D. Greenberg, Massimo Loda, Elaine R. Mardis, Elizabeth A. Platz, Michael N. Pollak, Robert D. Schreiber, Lillian L. Siu, Beverly A. Teicher

CANCER RESEARCH (2022)

Editorial Material Oncology

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission

Kenneth C. Anderson, Lewis C. Cantley, Riccardo Dalla-Favera, Chi Van Dang, Luis A. Diaz, Raymond N. DuBois, Keith T. Flaherty, Philip D. Greenberg, Massimo Loda, Elaine R. Mardis, Elizabeth A. Platz, Michael N. Pollak, Robert D. Schreiber, Lillian L. Siu, Beverly A. Teicher

CANCER IMMUNOLOGY RESEARCH (2022)

Article Oncology

Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations

Smruthy Sivakumar, Dexter X. Jin, Ruchita Rathod, Jeffrey Ross, Lewis C. Cantley, Maurizio Scaltriti, Jessica W. Chen, Katherine E. Hutchinson, Timothy R. Wilson, Ethan S. Sokol, Neil Vasan

Summary: The purpose of this study was to characterize the tissue-specific and molecular subclasses of multiple PIK3CA mutations and their impact on therapeutic outcomes. The results showed that multi-PIK3CA mutations accounted for 11% of all PIK3CA-mutant tumors and were enriched in breast and gynecologic cancers. These mutations frequently occurred in cis on the same allele and at characteristic positions across tumor types. Different classes of multi-PIK3CA mutant estrogen receptor-positive, HER2-negative breast cancers responded similarly to PI3K inhibition.

CLINICAL CANCER RESEARCH (2023)

Article Dermatology

Topical N-phosphonacetyl-l-aspartate is a dual action candidate for treating non- melanoma skin cancer

Kala K. Mahen, Lilian Markley, Jolie Bogart, Hope Klatka, Vijay Krishna, Edward V. Maytin, George R. Stark, Christine McDonald

Summary: Each year, millions of Americans are diagnosed with non-melanoma skin cancers (NMSC) and millions more receive treatment for precancerous actinic keratosis lesions. The current treatments, surgical excision and Mohs surgery, are invasive, expensive, and require specialized training. More accessible topical therapies exist, but they have significant side effects that limit their effectiveness. Therefore, there is a need for more effective and accessible treatments for NMSC and precancers.

EXPERIMENTAL DERMATOLOGY (2023)

Editorial Material Oncology

The Hallmarks of a Cancer Discovery

Luis A. Diaz, Lewis C. Cantley

CANCER DISCOVERY (2023)

Review Immunology

Chemical modulation of gasdermin D activity: Therapeutic implications and consequences

Bowen Zhou, Derek W. Abbott

Summary: This article discusses the current research progress on three inhibitors affecting the activity of gasdermin D and provides cautionary notes, as well as a set of guiding principles for researchers to consider when further studying gasdermin D inhibition.

SEMINARS IN IMMUNOLOGY (2023)

Review Oncology

Developing dietary interventions as therapy for cancer

Samuel R. Taylor, John N. Falcone, Lewis C. Cantley, Marcus D. Goncalves

Summary: This Review discusses metabolic alterations and vulnerabilities in different types of cancer, and suggests using dietary interventions in combination with pharmacologic therapies to target these changes. However, diet studies in cancer patients are rare and lack robust evidence. The article also explores how dietary strategies can be combined with pharmacological therapies in treating cancer.

NATURE REVIEWS CANCER (2022)

Article Biochemistry & Molecular Biology

A 3D-printable device allowing fast and reproducible longitudinal preparation of mouse intestines

Beckey DeLucia, Sergey Samorezov, Megan T. Zangara, Rachel L. Markley, Lucas J. Osborn, Karlee B. Schultz, Christine McDonald, Jan Claesen

Summary: This article presents a 3D-printed Mouse Intestinal Slicing Tool (MIST) for efficient longitudinal dissection of murine intestines. The MIST outperforms other methods in terms of smoothness and reproducibility, while reducing the time required for intestine preparation.

ANIMAL MODELS AND EXPERIMENTAL MEDICINE (2022)

暂无数据